<DOC>
	<DOC>NCT00600119</DOC>
	<brief_summary>Study (07-IN-NX003) is a Phase 2, multi-center, placebo-controlled, double-blind, randomized, dose-escalation trial. It is designed to investigate the safety, efficacy and tolerability of NKTR-118 (PEG-naloxol) in patients with opioid-induced constipation (OIC) and other clinical manifestations of opioid-induced bowel dysfunction (OBD). The objective of this study is to evaluate the safety, effectiveness and pharmacokinetics of NKTR-118 at 4 different doses.</brief_summary>
	<brief_title>A Phase 2, Double-Blind, Multiple-Dose Escalation Study to Evaluate NKTR-118 (Oral PEG-Naloxol) in Patients With Opioid-Induced Constipation (OIC)</brief_title>
	<detailed_description />
	<mesh_term>Constipation</mesh_term>
	<mesh_term>Analgesics, Opioid</mesh_term>
	<mesh_term>Naloxegol</mesh_term>
	<criteria>Main 18 years of age or older, male or female Receiving a stable opioid regimen Documented opioidinduced constipation Willingness to stop all laxatives and other bowel regimens. The use of constipation rescue medication will be allowed during the study. Main Life expectancy less than 6 months Active substance abuse Fecal incontinence, irritable bowel syndrome, inflammatory bowel disease, or other active medical disorders associated with diarrhea or intermittent loose stools or constipation Pregnant or breastfeeding Any receipt of an investigational medication within 30 days of screening History or presence of specific cardiac, neurologic, endocrine and/or psychiatric conditions</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>NKTR, constipation, opioid, induced, bowel, dysfunction, Naloxol, Naloxone, Narcan, PEG naloxol, OIC, OBD, Nektar</keyword>
</DOC>